Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

Arthritis Research & Therapy
Sergio SchwartzmanG James Morgan

Abstract

Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA--infliximab, etanercept, and adalimumab--have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy wi...Continue Reading

References

May 1, 1992·British Journal of Rheumatology·F M BrennanM Feldmann
Dec 1, 1996·International Archives of Allergy and Immunology·M Feldmann
Nov 14, 1997·Immunology Today·A EiglerS Endres
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
Nov 4, 1994·PharmacoEconomics·S H AllaireR F Meenan
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Sep 25, 2001·Lancet·D M Lee, M E Weinblatt
Feb 13, 2002·Arthritis and Rheumatism·UNKNOWN American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines
Apr 19, 2002·The Journal of Pharmacology and Experimental Therapeutics·Bernie ScallonCarrie Wagner
Jul 3, 2002·Pediatrics·UNKNOWN Committee on Drugs. American Academy of Pediatrics
Jul 12, 2002·Arthritis Research·Alan J Silman, Jacqueline E Pearson
Jul 12, 2002·Arthritis Research·Ravinder N Maini, Marc Feldmann
Aug 15, 2002·Annals of the Rheumatic Diseases·H M LapsleyUNKNOWN Arthritis Cost and Outcome Project Group

❮ Previous
Next ❯

Citations

Apr 10, 2014·Arthritis Research & Therapy·Kei IkedaHiroshi Nakajima
Jul 6, 2005·Clinical and Experimental Immunology·M Vigna-PérezR González-Amaro
Mar 1, 2016·Nature Reviews. Nephrology·Falk Hiepe, Andreas Radbruch
Jul 6, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J N Fain, A K Madan
Sep 21, 2005·Journal of Biochemical and Molecular Toxicology·Aziz QabarMark Steinberg
Sep 1, 2008·Expert Review of Clinical Immunology·Katherine Anne B Marzan, Andreas Otto Reiff
Sep 26, 2009·Toxicology Mechanisms and Methods·T AnandB K Bhattacharya
May 19, 2010·Expert Review of Clinical Immunology·Danial E Baker

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Software Mentioned

ATTRACT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.